"Creating Differences and Value for Human Health"
PBP's current biosimilar portfolio includes:
- HD201 (Herceptin Biosimilar)
- HD204 (Avastin Biosimilar)
- PBP1502 (Humira Biosimilar)
All currently under advanced clinical to nonclinical development stages. Based on the technology and capabilities established from the successful development of these biosimilars, the next tier of biosimilars as well as biobetter and new antibody therapeutics are under development in conjunction with reputable discovery institutions and academia.